BDSI Announces Positive Phase III Clinical Trial Results for BEMAâ„¢ Fentanyl
Primary Efficacy Endpoint in Pivotal Trial Demonstrates Statistical Significance Compared to Placebo in Patients with Breakthrough Cancer Pain
Company to Host Conference Call and Webcast at 11am Eastern Time Today to Discuss Results
MORRISVILLE, N.C. - BioDelivery Sciences International, Inc. announced today statistically significant results with BEMATM Fentanyl in cancer patients with breakthrough pain in its pivotal Phase III efficacy clinical trial for the product. The results are based on achievement of the primary efficacy endpoint of the trial, Summary of Pain Intensity Difference (SPID), compared to placebo.
The results demonstrated that patients treated with BEMATM Fentanyl showed a statistically significant improvement on the primary efficacy endpoint at 30 minutes (SPID 30) compared to placebo (p